載入中
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
最新資料
HK$3.91
−HK$0.135 · -3.34%
盤中時間採用HKT。市場資料可能有所延遲。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日內區間
目前HK$3.91
52週區間
目前HK$3.91
盤中時間採用HKT。市場資料可能有所延遲。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日內區間
目前HK$3.91
52週區間
目前HK$3.91
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9.11億 CNY | 3.68億 CNY | 2.25億 CNY | 1557.2萬 CNY | — |
| 銷貨成本 | 1.79億 CNY | 7482.4萬 CNY | 2827.7萬 CNY | 200.5萬 CNY | 1.15億 CNY |
| 毛利 | 7.32億 CNY | 2.93億 CNY | 1.97億 CNY | 1356.7萬 CNY | −1.15億 CNY |
| 研究與開發 | 3.36億 CNY | 4.38億 CNY | 4.58億 CNY | 5.24億 CNY | 7.91億 CNY |
| 銷售、一般及管理費用 | 3.54億 CNY | 2.38億 CNY | 1.3億 CNY | 1.41億 CNY | 1.56億 CNY |
| 營業費用 | 6.45億 CNY | 6.84億 CNY | 1.92億 CNY | 7.18億 CNY | 10.1億 CNY |
| 利息收入 | 1200.89萬 CNY | 466.7萬 CNY | 670.9萬 CNY | 817.3萬 CNY | 414.3萬 CNY |
| 利息支出 | 2855.05萬 CNY | 2165萬 CNY | 1467.7萬 CNY | 746.7萬 CNY | 269.6萬 CNY |
| 折舊和攤銷 | 9130.03萬 CNY | 8391.2萬 CNY | 1.03億 CNY | 9544.6萬 CNY | 7718.3萬 CNY |
| 營業利益 | 8743.01萬 CNY | −3.91億 CNY | 479.6萬 CNY | −7.04億 CNY | −10.1億 CNY |
| 淨利 | 2.55億 CNY | −4.11億 CNY | −2209.6萬 CNY | −6.89億 CNY | −10.11億 CNY |
公司資料更新於 2026年10月5日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
iShares Core MSCI Emerging Markets ETFIEMG614.72萬0.00%1621.9億 USD0.09%US$83.52+1.41%
State Street SPDR Portfolio Emerging Markets ETFSPEM102.76萬0.01%174.79億 USD0.07%US$52.765+1.65%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX31.88萬0.05%6.62億 USD0.65%US$71.77+0.60%
WisdomTree China ex-State-Owned Enterprises FundCXSE30.17萬0.07%4.49億 USD0.32%US$35.035+1.48%
Avantis Emerging Markets Equity ETFAVEM27.52萬—287.4億 USD0.33%US$96.61+1.26%
iShares Core MSCI Total International Stock ETFIXUS23.38萬0.00%590.95億 USD0.07%US$95.9685+0.41%
Global X - Aging Population ETFAGNG18.61萬0.21%8739.62萬 USD0.50%US$37.50+4.33%
iShares MSCI China Small-Cap ETFECNS17.46萬0.28%6174.66萬 USD0.59%US$27.31+0.81%iShares Core MSCI Emerging Markets ETFIEMGState Street SPDR Portfolio Emerging Markets ETFSPEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXWisdomTree China ex-State-Owned Enterprises FundCXSEAvantis Emerging Markets Equity ETFAVEMiShares Core MSCI Total International Stock ETFIXUSGlobal X - Aging Population ETFAGNGiShares MSCI China Small-Cap ETFECNSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
